In GD fibroblasts, Lacidipine at 10 µM for 24 hrs increased Bcl-2 expression by 3.0-fold compared with untreated cells. In Vero cells incubated with and without Lacidipine, GTOVpv and MOPVpv exhibited dose-dependent inhibition, with IC50s of 6.2 μM and 4.8 μM, respectively. In fibroblasts derived from GD patients homozygous for the L444P GC allele, Lacidipine at 20 µM for 48 hrs produced a 1.8-fold GC activity response compared with untreated cells. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Bcl-2 expression in GD fibroblasts
Cell-based study · GD fibroblasts [1]
GD fibroblasts were cultured with Lacidipine at 10 µM for 24 hrs. Treatment increased Bcl-2 expression by 3.0-fold compared with untreated cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM
- Exposure duration
- 24 hrs
- Method
- cells cultured with lacidipine
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Lacidipine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Lacidipine Remodels EerI-mediated Activation of the UPR Pathway (S77, S78); Figure 4 legend (S151)
Bcl-2 expression: Bcl-2 expression; comparator: untreated cells — Results > Lacidipine Remodels EerI-mediated Activation of the UPR Pathway (S77, S78)
Pseudotype inhibition in Vero cells
Cell-based study · Vero cells [2]
Vero cells were incubated in the absence and presence of Lacidipine, with luciferase activity assessed after pseudotype exposure. GTOVpv and MOPVpv exhibited dose-dependent inhibition, with IC50s of 6.2 μM and 4.8 μM, respectively.
Literature-Reported Treatment Conditions
- Exposure duration
- After 1 h, the pseudotypes of GTOV, JUNV, MACV, SABV, CHPV, LCMV, LUJV, MOPV, EBOV, and MARV were added at an MOI of 0.01. The supernatant was removed 1 h later, and the cell lysates were assessed for luciferase activity after 23 h.
- Method
- incubated in the absence and presence of lacidipine
- Co-treatment
- Other interventions in this design: GTOV MOI of 0.01. Compound effect isolated by the comparison: in the absence and presence of lacidipine.
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Lacidipine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Lacidipine affects entry of other arenaviruses. (S70); FIG 6 legend (S185, S186, S187)
luciferase activity: luciferase activity; comparator: in the absence and presence of lacidipine — RESULTS > Lacidipine affects entry of other arenaviruses. (S70); FIG 6 legend (S187)
GC activity in patient-derived GD fibroblasts
Cell-based study · fibroblasts derived from GD patients homozygous for the L444P GC allele [1]
Fibroblasts derived from GD patients homozygous for the L444P GC allele were cultured with Lacidipine at 20 µM for 48 hrs. The intact cell GC activity assay showed a 1.8-fold response compared with untreated cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 µM
- Exposure duration
- 48 hrs
- Method
- cultured in medium
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Lacidipine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Modulation of Ca2+ Homeostasis Enhances the Rescue of L444P GC Folding, Trafficking and Activity Induced by ERAD Inhibition in GD Fibroblasts (S13, S14, S15, S17, S18); Figure 1 legend (S133)
intact cell GC activity assay: intact cell GC activity assay; comparator: untreated cells — Results > Modulation of Ca2+ Homeostasis Enhances the Rescue of L444P GC Folding, Trafficking and Activity Induced by ERAD Inhibition in GD Fibroblasts (S15, S18)